Lung Cancer Screening in High-risk Black Women

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05898594
Collaborator
Agency for Healthcare Research and Quality (AHRQ) (U.S. Fed)
900
1
1
57
15.8

Study Details

Study Description

Brief Summary

The goal of this research study is to study U.S. Black women with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population.

The name of the intervention used in this research study is:

Low-dose computed tomography (radiologic scan) chest scan

Condition or Disease Intervention/Treatment Phase
  • Procedure: Low-dose Computed Tomography
N/A

Detailed Description

The goal of this single-arm pilot research study is to evaluate the feasibility and acceptability of low-dose computed tomography (LDCT) screening for lung cancer among U.S. Black women with a history of smoking.

LDCT screening is currently the only recommended way to screen for lung cancer among high-risk individuals. However, the majority of Black women at high-risk for lunch cancer are currently ineligible for lung cancer screening.

Study procedures include screening for eligibility, completion of questionnaires, and a LDCT screening test.

Participation in this study is expected to last up to 3 months.

It is expected about 900 people will participate in this study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
900 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Evaluating the Feasibility of Lung Cancer Screening in High-risk Black Women
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2028
Anticipated Study Completion Date :
Jun 30, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Screening: Low-Dose Computed Tomography Screening

Participants will undergo study procedures as outlined: Complete questionnaires pre- and post- low-dose computed tomography (LDCT) test. Visit Massachusetts General Hospital facility for a LDCT screening test.

Procedure: Low-dose Computed Tomography
Per standard care

Outcome Measures

Primary Outcome Measures

  1. Proportion of Enrolled Participants [At enrollment]

    Primary endpoint is feasibility. Feasibility is defined as the percentage of invited participants of the Black Women's Health Study (BWHS) who enroll.

  2. Proportion of Participants with Positive Low-dose Computed Tomography Test [At 3 months]

    The percentage of participants who have a positive low-dose computed tomography test will be evaluated. This percentage will be compared to the Black women randomized to the low-dose computed tomography screening arm in the National Lung Screening Trial (historical control).

  3. Proportion of Participants Diagnosed with Invasive Lung Cancer [At 6 months]

    The proportion of participants with a lung cancer diagnosis post-low-dose computed tomography screening test will be compared to Black women randomized to the LDCT screening arm in the National Lung Screening Trial (historical control).

  4. Distribution of Lung Imaging Reporting and Data System (Lung-RADS) Scores [At 3 months]

    The distribution of Lung-RADS scores among participants will be evaluated and compared to the distribution of Lung-RADS scores among Black women randomized to the LDCT screening arm in the National Lung Screening Trial (historical control).

Secondary Outcome Measures

  1. Proportion of Participants Who Undergo Invasive Diagnostic Procedures [At 6 months]

    The proportion of participants who undergo invasive diagnostic procedures will be evaluated and compared to the proportion of Black women randomized to the LDCT screening arm in the National Lung Screening Trial (historical control) who underwent invasive diagnostic procedures.

  2. Proportion of Participants Who Have a Complication Resulting from an Invasive Diagnostic Procedure Performed for a Positive Low-dose Computed Tomography Scan [At 6 months]

    The proportion of participants who have a complication resulting from an invasive diagnostic procedure performed for a positive low-dose computed tomography scan will be evaluated. This proportion will be compared to the proportion of Black women randomized to the low-dose computed tomography screening arm in the National Lung Screening Trial (historical control) who had a complication resulting from an invasive diagnostic procedure performed for a positive low-dose computed tomography scan.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Self-identified Black women.

  • Have a self-reported history of smoking. No restriction will be placed on the number of smoking pack years participants must have nor the number of years former smokers must have quit smoking.

  • Aged >= 50 years.

Exclusion Criteria:
  • Individuals with a history of lung cancer.

  • Individuals with symptoms suggestive of lung cancer. We will evaluate whether women have symptoms suggestive of lung cancer by administering an online screening questionnaire, which will ask whether they have experienced shortness of breath, whether they become easily winded, and whether they have had a chronic cough within the last 12 weeks that has not improved. Women who select that they have any one of these symptoms will be advised to follow up with their primary doctor and will not be eligible to participate in the study.

  • Individuals with pneumonia or acute respiratory infection within 12 weeks prior to enrollment that was treated with antibiotics.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Cancer Center Boston Massachusetts United States 02215

Sponsors and Collaborators

  • Massachusetts General Hospital
  • Agency for Healthcare Research and Quality (AHRQ)

Investigators

  • Principal Investigator: Chi Fu Jeffrey Yang, MD, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chi-Fu Jeffrey Yang, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05898594
Other Study ID Numbers:
  • 22-382
  • 1R18HS029430-01
First Posted:
Jun 12, 2023
Last Update Posted:
Jun 13, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Chi-Fu Jeffrey Yang, Principal Investigator, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 13, 2023